OBJECTIVE:
In order to differentiate between the normally grown fetus and the fetus with IUGR, we sought to determine if IUGR can be identified via biomarkers in cord blood at delivery and neonatal serum within the first week of life. STUDY DESIGN: This was a case-cohort study of liveborn nonanomalous chromosomally normal infants admitted to the NICU from April 2009 to March 2016. IUGR fetuses were defined as fetuses whose estimated fetal weight (EFW) was below the 10th percentile for gestational age. Pregnancies resulting in IUGR in this cohort were compared to the other normally grown fetuses without IUGR. Neonates with major congenital malformations, chromosomal abnormalities or brain injury were excluded. Neonates were longitudinally evaluated for seven serum biomarkers -glial fibrillary acidic protein (GFAP), vascular growth factor (VEGF), brain-derived neurotrophic factor (BDNF), neurogranin (NRGN), interleukin (IL)-6, IL-8 and IL-10 in cord blood at delivery and on day 4 of life (table 1). Multivariate marginal linear regression models models and repeated measures analysis of variance (ANOVA) were used to investigate the relationship between IUGR and biomarker, adjusting for gestational age, birth weight and mode of delivery. Statistical analysis was done using STATA 15. RESULTS: Of 2,204 pregnancies that met inclusion criteria, 445 (20.2%) were complicated by IUGR. Gestational ages ranged from 23.3 to 40.3 (mean 30.4) weeks, and mean birthweight was 1102 (AE478) vs 1567 (AE994) grams in cases and controls respectively. Mean VEGF levels were significantly lower at baseline (7.97 ng/mL in cases vs 91.34 ng/mL in controls; p¼0.016) and on day 4 of life (293.92 ng/mL in cases vs 335.77 ng/mL in controls; p¼0.047). Mean serum levels of GFAP, NRGN, BDNF, IL-8 and IL-6 were similar at baseline and on the 4 th day of life in IUGR fetuses compared to gestational age matched controls (table 1) . CONCLUSION: Compared to gestational age matched controls, IUGR fetuses had lower circulating levels of VEGF. Changes in biomarker levels associated with IUGR are potential novel pathways for identifying the pathologically growth restricted fetus, which will require further prospective validation.
Supported by NICHD R01HD086058. OBJECTIVE: Fetal lower urinary tract obstruction (LUTO) is commonly diagnosed during the second trimester anatomic survey. The choice of fetal candidates for fetal intervention is challenging and was historically based of fetal urinary biochemical markers. The aim of this study is to investigate a new scoring system for selecting the fetuses with severe LUTO who could benefit from prenatal interventions as demonstrated by neonatal survival at the age of 6 months. STUDY DESIGN: Retrospective review of all cases of isolated severe LUTO with normal karyotype who were managed and delivered at our institute between 2013 and 2017 was performed. Baseline demographic characteristics, data about fetal interventions, and neonatal survival were collected. Severe fetal LUTO is defined as the presence of severe oligohydramnios/anhydramnios, megacystis, bilateral hydronephrosis and hydroureters). Only male fetuses are included in our study. A scoring system composed of initial fetal bladder volume, percentage of bladder refill in 48 hours after bladder tap, evidence of dysplastic changes of the fetal kidneys by ultrasound and fetal urinary biochemistry (1 score for each) was suggested. ROC curve was performed to determine the area under the curve (AUC) for perinatal mortality at 6 months.
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